| 2026-03-10 |
详情>>
股本变动：
变动后总股本1719.76万股
|
| 2026-03-10 |
详情>>
业绩披露：
2025年年报每股收益-1.34美元,归母净利润-5259.9万美元,同比去年增长-198.82%
|
| 2025-12-08 |
详情>>
内部人交易：
Rich Stuart股份增加2500.00股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.96美元,归母净利润-3705.9万美元,同比去年增长-226.94%
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.56美元,归母净利润-2125.5万美元,同比去年增长-188.22%
|
| 2025-06-21 |
复牌提示：
2025-06-20 13:39:37 停牌，复牌日期 2025-06-20 13:44:37
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.28美元,归母净利润-1040.8万美元,同比去年增长-173.98%
|
| 2025-04-25 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect the directors named in the Proxy Statement for a one-year term expiring in 2026 or until their successors have been elected and qualified;
2.To approve the Certificate of Amendment to the Company’s Certificate of Incorporation to reflect recently amended Delaware General Corporate Law provisions regarding officer exculpation;
3.To approve the Certificate of Amendment to the Company’s Certificate of Incorporation to require all stockholder action be taken at an annual or special meeting of stockholders;
4.To hold an advisory (nonbinding) vote on named executive officer compensation;
5.To hold an advisory (nonbinding) vote on the frequency of future advisory votes on named executive officer compensation;
6.To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
7.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2025-03-25 |
详情>>
业绩披露：
2024年年报每股收益-1.15美元,归母净利润-1760.2万美元,同比去年增长-128.28%
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.37美元,归母净利润-1133.5万美元,同比去年增长-152.73%
|
| 2024-09-27 |
股东大会：
将于2024-10-25召开股东大会
会议内容 ▼▲
- 1.To approve Amendment No. 2 to our 2022 Stock Incentive Plan, as amended to increase the number of shares authorized for issuance under the plan by 7,935,912 shares;
2.To approve the adjournment of the Special Meeting, if necessary, to permit further solicitation and vote of proxies, if there are not sufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to approve Proposal 1;
3.To consider and take action upon such other matters as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-4.65美元,归母净利润-737.45万美元,同比去年增长-193.44%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-3.12美元,归母净利润-379.88万美元,同比去年增长-170.04%
|
| 2024-04-26 |
股东大会：
将于2024-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the directors named in the Proxy Statement for a one-year term expiring in 2025 or until their successors have been elected and qualified;
2.To approve Amendment No. 1 to our 2022 Stock Incentive Plan to increase the number of shares authorized for issuance under the plan by 400,000 shares;
3.To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-31.04美元,归母净利润-771.07万美元,同比去年增长30.21%
|
| 2024-01-03 |
详情>>
拆分方案：
每80.0000合并分成1.0000股
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.24美元,归母净利润-448.51万美元,同比去年增长47.23%
|
| 2023-10-27 |
股东大会：
将于2023-11-30召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, the decision whether to implement which split, its implementation and timing, being subject to the discretion of the Board of Directors;
2.To approve the adjournment of the Special Meeting, if necessary, to permit further solicitation and vote of proxies, if there are not sufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to approve Proposal 1;
3.To consider and take action upon such other matters as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2023-04-28 |
股东大会：
将于2023-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the directors named in the Proxy Statement for a one-year term expiring in 2024 or until their successors have been elected and qualified;
2.To approve an amendment to our certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, the decision whether to implement which split, its implementation and timing, being subject to the discretion of the Board of Directors;
3.To approve Amendment No. 1 to our 2022 Stock Incentive Plan to increase the number of shares authorized for issuance under the plan by 2,750,000 shares;
4.To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.To approve the adjournment of the Annual Meeting, if necessary, to permit further solicitation and vote of proxies, if there are not sufficient votes at the time of the Annual Meeting or any adjournment or postponement thereof to approve one or more of the proposals presented at the Annual Meeting;
6.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2023-01-05 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2022-04-28 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the directors named in the Proxy Statement for a one-year term expiring in 2023 or until their successors have been elected and qualified;
2.To approve an amendment to our certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, the decision whether to implement which split, its implementation and timing, being subject to the discretion of the Board of Directors;
3.To approve the Tenax Therapeutics 2022 Stock Incentive Plan;
4.To hold an advisory (nonbinding) vote on named executive officer compensation;
5.To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
6.To consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.The election of the nine director nominees described in the Proxy Statement to serve as directors until the sooner of the 2022 Annual Meeting of Stockholders or the election and qualification of their successors;
2.To approve the conversion of our Series B Preferred Stock into shares of common stock;
3.To approve Amendment No. 2 to our 2016 Stock Incentive Plan to increase the number of shares authorized for issuance under the plan by 750,000 shares;
4.The ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
|
| 2020-04-29 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.the election of the six director nominees described in the Proxy Statement to serve as directors until the sooner of the 2021 Annual Meeting of Stockholders or the election and qualification of their successors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
|
| 2019-04-19 |
股东大会：
将于2019-06-13召开股东大会
会议内容 ▼▲
- 1.the election of the six director nominees described in the Proxy Statement to serve as directors until the sooner of the 2020 Annual Meeting of Stockholders or the election and qualification of their successors;
2.the approval of Amendment No. 1 to our 2016 Stock Incentive Plan to increase the number of shares authorized for issuance under the plan by 600,000 shares;
3.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.the advisory (nonbinding) approval of named executive officer compensation;
5.the advisory (nonbinding) vote on the frequency of future advisory votes on named executive officer compensation.
|
| 2018-04-20 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.the election of the six director nominees described in the Proxy Statement to serve as directors until the sooner of the 2019 Annual Meeting of Stockholders or the election and qualification of their successors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.At the Annual Meeting we may transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-02-23 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2018-01-16 |
股东大会：
将于2018-02-15召开股东大会
会议内容 ▼▲
- 1.to approve an amendment to our certificate of incorporation to effect a reverse stock split (the “reverse stock split”) at a ratio of not less than one-for-five and not more than one-for-fifty at any time prior to December 31, 2018, with such ratio and the implementation and timing of such reverse stock split to be determined by our board of directors in its sole discretion;
2.to approve a proposal to adjourn the special meeting, if necessary or appropriate, to solicit additional proxies for any proposal if there are not sufficient votes to approve Proposal No. 1.
|
| 2017-04-28 |
股东大会：
将于2017-06-14召开股东大会
会议内容 ▼▲
- 1.the election of the six director nominees described in the Proxy Statement to serve as directors until the sooner of the 2018 Annual Meeting of Stockholders or the election and qualification of their successors;
2.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.the advisory (non-binding) approval of Named Executive Officer compensation.
|
| 2016-04-26 |
股东大会：
将于2016-06-16召开股东大会
会议内容 ▼▲
- 1.the election of the seven director nominees described in the Proxy Statement to serve as directors until the sooner of the 2017 Annual Meeting of Stockholders or the election and qualification of their successors;
2.to approve the Tenax Therapeutics, Inc. 2016 Stock Incentive Plan;
3.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
|
| 2015-08-17 |
股东大会：
将于2015-09-15召开股东大会
会议内容 ▼▲
- 1.the election of the seven director nominees described in the Proxy Statement to serve as directors until the sooner of the 2016 Annual Meeting of Stockholders or the election and qualification of their successors;
2.to approve Amendment No. 3 to our 1999 Amended Stock Plan to increase the number of shares authorized for issuance thereunder;
3.the ratification of the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending April 30, 2016;
4.the advisory (nonbinding) approval of named executive officer compensation.
|